Journal
AMERICAN JOURNAL OF PATHOLOGY
Volume 174, Issue 6, Pages 2035-2043Publisher
ELSEVIER SCIENCE INC
DOI: 10.2353/ajpath.2009.080924
Keywords
-
Categories
Funding
- Susan G. Komen for the Cure [BCTR0403075]
- Cure Dissertation Award
- US Department of Army [DAMD17-98-1-8144]
- NCI/NIH [RO1 CA90291]
- National Research Council of Argentina
- NATIONAL CANCER INSTITUTE [R01CA090291] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Caveolin-1 has been linked to tumor progression and clinical outcome in breast cancer, but a clear resolution of its role as a prognostic marker is lacking. We assessed caveolin-1 levels in normal breast tissue and two breast cancer cohorts for which outcome data were available. We found that caveolin-1 was not expressed in normal breast luminal epithelium but was present in the epithelial compartment of some tumors. We found no association between caveolin-1 expression in the epithelial compartment and clinical outcome. However, high levels of caveolin-1 in the stromal tissue surrounding the tumor, rather than within tumor cells, associated strongly with reduced metastasis and improved survival (P < 0.0001). The onset of mammary tumors driven by Her2/neu overexpression was accelerated in mice lacking caveolin-1, thereby supporting the observation that the presence of caveolin-1 in the tumor microenvironment modulates tumor development. These studies suggest that stromal caveolin-1 expression may be a potential therapeutic target and a valuable prognostic indicator of breast cancer progression. (Ant J Pathol 2009, 174:2035-2043; DOI:10.2353/ajpath.2009.080924)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available